Supporting health through research and education.

Grant Recipients » 2015

The Manitoba Medical Service Foundation has been awarding Research Grants to researchers since 1971, and over $14 million has been donated to furthering this cause, with over $19 million provided in support of all awards.

We only keep the last five consecutive years of Grant Recipients online. Contact the Administrative Assistant for information on prior years.

Please Note: Institutional Costs are not eligible expenses for MMSF Grants and Awards funding.

Human Milk Composition and Early Childhood Overweight

  • PhotoDr. M. Azad

Award icon $10,750

Award icon $10,750 (CHRIM)

Childhood obesity is a major public health challenge in Canada and around the world. Rates have doubled since the 1970s, with nearly one in three Canadian children now classified as overweight or obese. Alarmingly, over 20 per cent of preschool children are overweight, indicating that obesity is a problem that begins very early in life. Breastfeeding can be protective against childhood obesity, but the milk components responsible for this effect are not known, and some breastfed infants still become overweight or obese. The inconsistent success of breastfeeding in preventing childhood obesity could be related to breast milk composition, but this has not been widely studied.

In the proposed study, we will investigate the association of breast milk composition with early childhood obesity. Leveraging resources from the Canadian Healthy Infant Longitudinal Development (CHILD) national birth cohort, we will determine the effect of breast milk composition on childhood obesity up to three years of age, focusing on two bioactive milk components: fatty acids and adipose-derived hormones. Breast milk will be analyzed for a subset of 432 participants from the CHILD study, and overweight children will be classified according to World Health Organization guidelines at one and three years using direct measurements taken at CHILD clinic visits. Milk composition will be measured and compared between normal weight and overweight children, with adjustment for important obesity risk factors including ethnicity, socioeconomic status, diet, maternal obesity and smoking.

Our study will contribute important new results on the effect of breast milk composition on early childhood obesity. This will improve our understanding of the biological mechanisms underlying the anti-obesity effect of breastfeeding, which in turn will inform future research on nutrition-based approaches for obesity prevention. For example, recommendations might include modifying maternal diet to optimize breast milk composition or developing improved infant formula for those who cannot breastfeed.

  • Dr. Meghan Azad — Postdoc Fellowship (Pediatrics) (University of Alberta) 2014; PhD (Biochemistry and Medical Genetics) (University of Manitoba) 2010; BSc (Honours) (Biochemistry) (University of Winnipeg) 2004

    Assistant Professor, Pediatrics and Child Health, University of Manitoba

    Research Scientist, Children's Hospital Research Institute of Manitoba

    Riverview Manager, Knowledge Synthesis Platform, George & Fay Yee Centre for Healthcare Innovation

Effect of an Exercise Rehabilitation Program on Physical Function in Incident Hemodialysis Patients: A Randomized Controlled Pilot Study

  • PhotoDr. C. Bohm

Award icon $10,500

Award icon $10,500 (WF)

People with advanced kidney failure who need to start dialysis treatment often have low levels of physical activity and physical function. This affects their ability to perform everyday activities and enjoy life. It also increases the long-term risk of being admitted to hospital, requiring a nursing home, or dying.

This study will assess whether an exercise rehabilitation program, started within a few weeks of beginning dialysis, can improve physical function, physical activity and well-being. In order to test this idea, we will enroll 28 volunteers who have recently started dialysis. Half of the patients will be randomized to receive usual care, which includes education about the importance of physical activity. The other 14 volunteers will be randomized to receive usual care plus a 12-week exercise rehabilitation program designed to improve physical function. We will then compare the results of the two groups to see if the rehabilitation program has had any effect on physical function, physical activity level and general well-being over a six-month period.

Although the primary goal of this small study is to determine if completion of a similar, larger study is possible, we hope to show that early exercise rehabilitation is an effective way to improve physical function and other health outcomes in dialysis. In Manitoba, which has one of the highest rates of kidney disease requiring dialysis in Canada, such improvements would be important for individual patient and caregiver health and well-being. In addition, such improvements to individual health have the potential to reduce both the burden and the cost to our health care system overall.

  • Dr. Clara Bohm — MPH (Epidemiology) (John Hopkins University) 2014; FRCPC (Nephrology) (Dalhousie University) 2002; FRCPC (Internal Medicine) (University of Saskatchewan) 1999; MD (Medicine) (McMaster University) 1995; BSc (Honors) (Life Sciences) (Queens University) 1992

    Assistant Professor, Internal Medicine / Nephrology, University of Manitoba

    Nephrologist, WRHA

    Medical Lead, Exercise and wellness Program, Manitoba Renal Program

Omega-3 Fatty Acid Supplementation and Resistance Training on Inflammation and Body Composition in Older Adults

  • PhotoDr. S. Cornish

Award icon $9,500

Award icon $9,500 (WF)

The loss of skeletal muscle mass and muscle strength is associated with the aging process. It can lead to a number of difficulties in maintaining daily living activities, and increase the risk of falling in older adults. It is thought that the loss of muscle mass and strength with age is due to a number of factors, including physical inactivity, poor nutritional intake, changes in hormone levels, and an increase in the amount of inflammation that is present in the body.

There are various methods that have been used to maintain or increase the amount of skeletal muscle mass and strength in older adults. However, it seems the most effective method is for older adults to participate in a resistance training exercise program. Using omega-3 fatty acid supplements seems to be an ideal method to decrease the inflammation that is associated with the aging process. Furthermore, omega-3 fatty acid supplementation may help to build muscle mass and strength in older adults.

The intent of this research is to evaluate the possible effects of combining two interventions: resistance training and omega-3 fatty acid supplementation. For 12 weeks, one group will receive the combined intervention, while the second will receive resistance training and a placebo supplement. This research is significant as it will help establish whether or not using resistance training combined with omega-3 fatty acid supplementation will help in decreasing the inflammation associated with the aging process, and increase the amount of muscle mass, strength and functional ability in older adults.

  • Dr. Stephen Cornish — PhD (Kinesiology) (University of Saskatchewan) 2008; MSc (Kinesiology) (University of Saskatchewan) 2001; BSc (Physical Education) (University of Saskatchewan) 1997

    Assistant Professor, Kinesiology & Recreation Management, University of Manitoba

    Research Affiliate, Health Leisure and Human Performance, University of Manitoba

    Research Affiliate, Centre on Aging, University of Manitoba

Inhibitors of the Pseudomonas aeruginosa Virulence Factor LasB

  • PhotoDr. R. Davis

Award icon $19,000

Antibiotic resistance in bacterial pathogens has become a serious threat to human health worldwide. The development of drug resistant bacterial strains is making drug therapy an ever-increasing challenge. With the number of antibiotic resistant bacterial strains rapidly increasing and the development of new antibiotics in steady decline, it is clear that new treatments for bacterial infections are a necessity. Pseudomonas aeruginosa (PsA) is the bacterium responsible for many hospital-acquired infections and also life-threatening chronic infections in patients with cystic fibrosis. Pseudomonas elastase (LasB), a key enzyme of PsA, causes damage to host tissue and interferes with the immune defense systems. The development of inhibitors of LasB should result in making PsA more susceptible to attack by the host immune system or other antibiotics.

In this proposal, we aim to develop small molecule inhibitors of LasB, an extracellular virulence factor of PsA. To develop LasB inhibitors, we propose to use a combination of computational modeling and chemical synthesis. Our computational models will provide us with vital information as to how the enzyme interacts with small molecules. Using this information, we will synthesize compounds and assess their ability to inhibit LasB. The proposed methodology is designed to be an iterative process in which the inhibition data collected from the first generation of small molecules will help us refine our computational models and the development of later generations of better compounds. Through this process, we will be able to develop highly-specific potent inhibitors of the PsA virulence factor LasB. The development of these small molecule inhibitors could lead to the creation of new drug treatments for combating PsA infections that will help decrease the incidence of antibiotic resistance and increase survival rates in cystic fibrosis patients.

  • Dr. Rebecca Davis — PhD (Organic Chemistry) (University of California, Daivs) 2011; BSc (Chemistry) (Washington State University) 2006

    Assistant Professor, Chemistry, University of Manitoba

Interaction of Gold Nanoparticles with Proteins Studied by Atomistic Simulations

  • PhotoDr. C. Deng

Award icon $11,000

During the past decade, nanomedicine has emerged as the main driving force for medicinal innovations. Nanomedicine is now attracting worldwide research and commercialization efforts for its great promise in benefiting human health. The current dominance of nanomedicine research focuses on the use of nanoparticles (particles less than 1,000 nanometres) for various applications, such as in vivo imaging and drug/gene delivery. Gold nanoparticles (AuNPs), which have been used for clinical purposes since the 1970s, are considered the most promising nanoparticles for biomedical applications due to the relatively easy synthesis and high controllability over size and morphology.

However, the interaction of AuNPs with a biological medium, particularly the adsorption of proteins on the AuNP surface, is not well understood. In particular, the nanotoxicity of AuNPs (which correlates to the possible conformational change of proteins after being bounded to the AuNPs), is a critical concern to human health. Therefore, despite the vast number of current experimental studies on the protein-AuNP interactions, some fundamental mechanisms remain unclear. Biological processes, such as the folding of proteins, require nanoscale accuracy on the measurement of both length (nm) and time (ns), which are beyond the scope of current experimental approaches.

The proposed research project will focus on theoretical modeling and use molecular dynamics (an atomistic computational simulation tool) to investigate the atomistic details of the protein-AuNP interactions. The project will begin by validating the important force field that characterizes the interatomic interactions between all atoms in the modeled protein-AuNP complex. Once established, the influences of size, conformation and surface characteristics of AuNPs on the adsorption and conformational changes of proteins will be systematically investigated. It is expected that the proposed theoretical research will complement the active experimental studies in this field and advance the understanding of the cytotoxicity of AuNPs for various biomedical applications.

  • Dr. Chuang Deng — PhD (material Science) (University of Vermont, USA) 2009; BSc (Materials Physics) (Fudan University, China) 2003

    Assistant Professor, Mechanical Engineering, University of Manitoba

Autophagy is a Target for Modulation of Epithelial Mesenchymal Transition in Lung Cancer

  • PhotoDr. S. Ghavami

Award icon $20,500

Lung cancer is considered one of the leading causes of cancer-related deaths around the world. The average survival time of lung cancer patients is very short. In Canada, on average, one in every 12 Canadians will develop lung cancer during their lifetime. Moreover, every day an average of 70 Canadians are diagnosed with lung cancer and 55 die of it.

Metastasis is one of the most serious risks in lung cancer, which causes the spreading of tumor cells to a secondary organ. One of the key elements involved in the metastasis process is changing epithelial cells to mesenchymal cells. Autophagy (self-eating) is a fundamental cellular and physiological process, and is a defensive mechanism against stress condition in the cells. Autophagy plays an essential role in cellular housekeeping by removing damaged and dysfunctional organelles and misfolded toxic aggregate-prone mutant proteins. Autophagy is a tightly regulated mechanism and plays an important function in many cancers.

In this project, we plan to address if autophagy occurs in mechanisms which are involved in cancer cell invasions and in spreading lung cancer. We plan to target autophagy to modulate cancer cell metastasis in lung cancer. We hope our project opens a new avenue to decrease lung cancer cell invasion.

  • Dr. Saeid Ghavami — PhD (Clinical Biochemistry) (Tarbiat Modarres University, Iran) 2004; MSc (Clinical Biochemistry) (Tarbiat Modarres University, Iran) 1996; BSc (Shiraz University, Iran) 1989

    Assistant Professor, Human Anatomy and Cell Science, University of Manitoba

    Assistant Professor, Children's Hospital Research Institute of Manitoba

    Honorary Adjunct Professor, Health Policy Research, Shiraz Medical University

Cyclic Polymer Scaffolds for Enhanced Platinum Chemotherapy Drug Delivery

  • PhotoDr. D. Herbert

Award icon $21,000

Platinum-based drugs are hugely important in the fight against cancer. Since the clinical approval of the earliest known example (cisplatin), the cure rate for testicular cancer has jumped from 10 per cent to 90 per cent, a testament to the effectiveness of modern platinum chemotherapy. Cisplatin is also a versatile drug, used by nearly half of all cancer patients to treat a variety of cancers. Remarkably, the effectiveness of platinum chemotherapy is thanks to only the very small percentage of the administered drug that reaches its intended cancer target. Unfortunately, treatment can be curtailed by severe side-effects caused by the vast majority of the administered drug that typically does not reach its target, and instead ends up wreaking havoc elsewhere in the body. Addressing this imbalance by improving the delivery of platinum compounds to tumours has the potential to both significantly enhance the effectiveness of platinum chemotherapy and reduce its debilitating side effects.

Our proposal outlines a novel strategy for platinum drug delivery that exploits the ability of ring-shaped macrocyclic polymers to accumulate and potentially penetrate deep into tumours. We will develop synthetic routes to biocompatible macrocycles that can then be decorated with different platinum-containing units. These units will be designed to release reactive platinum preferentially when exposed to conditions particular to cancer cells. By constructing similarly-sized linear analogues, we will be able to distinguish the effects of polymer architecture from those of size alone. We can then study the influence of polymer architecture on the behaviour of these polymer-platinum conjugates in solution. In addition, we can identify related properties that are important to improving targeted delivery and release of platinum drugs. By understanding the relationship between a conjugate's architecture, its properties and, ultimately, its function, these investigations will enable the identification of the best drug candidates to further develop into clinically useful, next-generation platinum-containing cancer chemotherapeutics.

  • Dr. David Herbert — Postdoc Fellowship (Chemistry) (Texas A & M University) 2013; PhD (Chemistry) (University of Bristol) 2010; MSc (Chemistry) (University of Toronto) 2006; BSc (Honours) (Chemistry) (University of King's College) 2004

    Assistant Professor, Chemistry, University of Manitoba

Patient-Specific Pathway Activations Inferred from Genomic Data Predict Breast Cancer Survival

  • PhotoDr. P. Hu

Award icon $18,000

Breast cancer is one of the most common causes of cancer death in Manitoban women. There are about 900 women in Manitoba diagnosed with breast cancer every year and about 25 per cent of them will die from this disease. Improving the detection of breast cancer at its earliest stages is one key to increasing survival. To do so, it is vital to identify molecular biomarkers.

We hypothesize that pathway biomarkers, which aggregate the gene activations in a pathway, are more robust than gene biomarkers. We further hypothesize that patterns of pathway co-activation can improve the prediction of breast cancer survival.

Although it is still quite expensive to perform genomic and transcriptomic profiling of cancer genomes using high-throughput technologies, the profiles of roughly 200 Manitoba breast cancer patients are available through the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), the largest human genomic data sets generated in Manitoba.

Our objectives are to discover pathway biomarkers for breast cancer using the patterns of pathway activation inferred from breast cancer genomic and transciptomic data sets generated in the METABRIC study, and to develop novel computational algorithms for inferring pathway activations in breast cancer patients.

We anticipate that our study will generate invaluable insights into the understanding of the tumor genomes of breast cancer. The genomic findings of the proposed project could lead to more cost-efficient and improved screening of earlier breast cancers and improved clinical outcomes. The availability of the advanced software tools from the study for more effective molecular diagnostic and prognostic tests promises to revolutionize personalized medicine in Manitoba.

  • Dr. Pingzhao Hu — PhD (Computer Science) (York University) 2012; MSc (Computer Science) (Dalhousie University) 2002

    Assistant Professor, Biochemistry and Medical Genetics, University of Manitoba

    Assistant Professor, Data Science Platform, George Fay Yee Centre for Healthcare Innovation

    Scientist, Children's Hospital Research Institute of Manitoba

    Assistant Professor (Status), Division of Biostatistics of Dalla Lana School of Public Health, University of Toronto

Predicting Emergence of Levodopa-Induced Dyskinesia (A Common Side Effect) in Parkinson’s Disease by a Brain Imaging-Based Biomarker – A Pilot Study

  • PhotoDr. J. Ko

Award icon $21,500

Parkinson's disease (PD) is the second most common neurodegenerative disorder next to Alzheimer's disease. In Canada, nearly 100,000 people are believed to suffer from PD. With an aging population, the burden on society is expected to greatly increase.

Levodopa has been the first-line anti-Parkinson therapy since its introduction in the 1960s. However, no fundamental cure for the disease yet exists. In the course of the disease progression, more than 50 per cent of patients will develop motor skill side effects, such as levodopa-induced dyskinesia (LID), which refers to involuntary muscle movement. LID is one of the most critical factors that deteriorate a patient's quality of life in the later stage of the disease.

Once LID becomes too severe (average 12-15 years from initial diagnosis of PD), surgical interventions are often recommended, such as deep brain stimulation (DBS). DBS will allow reduction of the necessary levodopa dosage for patients. Ironically, at the advanced stage, fewer patients qualify for surgical treatment due to old age, cognitive impairment and other health-related problems. In fact, less than 20 per cent of PD patients qualify for DBS. Therefore, it has been debated whether we have to shift the time of surgical intervention to an earlier stage. This may also benefit patients by reducing chronic levodopa exposure; the toxicity of which may facilitate disease progression.

The biggest challenge of moving forward with early surgical intervention is that it has been impossible to predict who may develop severe LID in the course of disease progression and treatment. We propose a brain imaging-based biomarker test to discover the patient’s susceptibility to LID. Based on our recent observation, cerebral blood overflow in the selective brain regions by levodopa administration was only distinct in PD patients with LID, but not with patients without LID. If successful, the result of this LID susceptibility test may be included in the referral guideline for surgical intervention.

  • Dr. Ji Hyun Ko — PhD (Neurological Science) (McGill University) 2009; BSc (Electrical and Computer Engineering) (Hanyan University) 2004

    Assistant Professor, Human Anatomy and Cell Science, University of Manitoba

    Principal Investigator, Neuroscience Research Program, Health Sciences Centre

    Adjunct Member, Graduate Program in Biomedical Engineering, University of Manitoba

Investigation of Underlying Molecular Pathologic Process Reflecting Apparent Diffusion Coefficient (ADC) Value and Imaging Biomarker Development for Chemo/Radiation Sensitivity in Human Glioma

  • PhotoDr. K. Matsuda

Award icon $21,500

Brain cancer is one of the most difficult types of cancer to manage because of the complexity of the brain. Therefore, any medical interventions – such as surgical resection, biopsy sampling, chemotherapy injection or irradiation— have to be undertaken with maximum caution to avoid seriously adverse effects. As such, non-invasive methods are preferable to monitor changes in the brain over time. Due to their ability to non-invasively visualize the internal condition of the human body, the advancement of medical imaging technologies is the key component in the development of new brain cancer therapies.

Our goal is to enhance the power of medical imaging, specifically MRI, for monitoring the treatment response of chemo/radiation therapy against brain tumors. MRI technologies are advanced so that subtle changes in the human tissue can be visualized with physicochemical signals generated by the magnet. Our approach uses cutting-edge MRI with a powerful magnet to scan surgically removed brain cancer (ex vivo tissue imaging). It can achieve microscopic resolution to study histopathology correlations at the cellular level.

Recent advancements in molecular-targeted drugs prompted us to search for reliable molecular markers that can predict therapeutic responses (biomarkers). Among them, a promising candidate called IDH-1 has been extensively studied in aggressive brain cancer, high-grade glioma. Experimental studies demonstrated complex interaction between IDH-1 and other important biomolecules, including hypoxic oxidative pathway and apoptosis. Thus, it is essential to analyze multiple molecules simultaneously in glioma cells. As such, we are incorporating a new technology called multiplex tissue immunoblotting—capable of multiplex molecular analysis - which can be accurately correlated with histology slides. Therefore, our approach can further establish a reliable correlation with histology and molecular data to achieve our goal.

  • Dr. Kant Matsuda — PhD (Molecular Biology) (Jichi Medical School) 2001; MD (Medicine) (Kobe University) 1995

    Assistant Professor, Pathology, University of Manitoba

Transport-Related Motion in Individuals Receiving Spinal Immobilization During Pre-Hospital Emergency Care

  • PhotoDr. R. Pryce

Award icon $11,000

Nearly all Canadians that sustain serious injuries to their spine will be transported to hospital in an ambulance. During transport, paramedics must ensure the injured area is immobilized, as excessive motion can cause further damage to nearby bones, nerves and spinal cord. The primary method paramedics use to restrict motion is fitting a hard collar around the patient's neck and securing the patient to a rigid backboard. We know this approach is effective while patients are secured and loaded into an ambulance; however, this has not been studied during the actual transport to hospital. In addition to driving tasks such as accelerating and turning, poor road conditions may cause increased motion leading to excessive movement of the injured patient. In order to ensure that delivery to hospital is safe and effective, we need to understand how much patient motion occurs during transport.

One of the reasons ambulance transport has not been well studied is a lack of suitable methods to measure patient movement in the confined space of an ambulance. Our lab has developed a unique method to accurately measure patient motion in these conditions using wireless miniature motion sensors. This study will be one of the first to measure how much movement occurs during actual ambulance transport and will quantify the influences of different road conditions and driving tasks. We will also compare two methods of immobilizing patients, in order to determine if one is more effective at limiting patient movement during transport.

Understanding how ambulance motion and road conditions influence patient movement will help medical practitioners make decisions about how to transport injured patients to hospital safely and effectively. The goal of this research is to help improve the direct medical care of the many Manitobans transported by ambulance each year.

  • Dr. Rob Pryce — PhD (Applied Health Sciences) (University of Manitoba) 2013; MSc (Rehabilitation Science) (University of Manitoba) 2008; BA (Kinesiology) (University of Winnipeg) 2003

    Assistant Professor, Kinesiology and Applied Health, University of Winnipeg

    Adjunct Professor, School of Medical Rehabilitation, University of Manitoba

Validation of PRDX1 as a Therapeutic Target that Mediates Radiation Resistance in Group-3 Medulloblastoma

  • PhotoDr. M. Vanan

Award icon $21,500

Medulloblastoma (MBL) is the most common brain cancer in children. Treatment includes surgery (to remove tumor), chemotherapy (pills and injections), and high-dose radiation therapy (to brain, spinal cord). Roughly 40 per cent of children with MBL do not respond to treatment and die. Children who do survive have serious side effects due to radiation, including mental retardation, hormone problems, vision and hearing problems, as well as secondary cancers in the brain. Recently, scientists have described four groups of MBL— Group 1-4. The majority of children (70 per cent) with group-3 MBL respond poorly to treatment and die of the disease.

The PRDX1 protein is known to protect brain and lung cells from radiation-induced damage and death. Based on evidence from literature, we think that the PRDX1 protein is present at high levels in group-3 MBL and is the cause for poor response to radiation treatment.

Firstly, we hope to find out whether PRDX1 is increased in group-3 MBL. Next, whether a decrease in PRDX1 levels or inhibition of the protein (using a chemical, adenanthin) in group-3 MBL tumor cells can kill more cells with less radiation. Lastly, we will use interventional radiology treatment on mice bearing group-3 MBL tumors with low PRDX1 protein and see whether radiation increases their survival time when compared to mice bearing tumors with normal PRDX1 levels.

This project will help us validate adenanthin as a potential new drug (along with low-dose radiation) to use in treatment of MBL in children, and help determine if increasing the response and decreasing the dose of radiation will decrease the side effects of treatment and improve quality of life for children with cancer.

PRDX1 protein levels are present at high levels in other cancers (lung, breast and prostate). Adenanthin along with low dose radiation treatment could also be tested on all these types of cancers.

  • Dr. Magimairajan Vanan — Fellowship (Pediatric Neuro-Oncology) (Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, USA) 2010; Fellowship (Pediatric Hematology-Oncology) (Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, USA) 2009; MD (Pediatrics) (Brookdale University Hospital and Medical Center, Brooklyn, NY, USA) 2006; MD (Pediatrics) (Postgraduate Institute of Medical Education and Research, Chandigarh, India) 1997; MBBS (Medicine, Surgery, OBG) (Bangalore Medical College and Research Institute, Bangalore, India) 1992

    Assistant Professor, Pediatrics and Child Health / Pediatric Hematology-Oncology / Pediatric Neuro-Oncology, University of Manitoba

    Pediatric Neuro-Oncologist, Pediatrics and Child Health, Pediatric Hematology-Oncology, CancerCare Manitoba

    Scientist, Fr Peter J McKenna St. Baldrick's Scholar, Oncology and Cell Biology, Manitoba Institute of Cell Biology

    Affiliate Scientist, Biochemistry and Medical Genetics, University of Manitoba

Life After Discharge: How Mobility Measured During and Immediately Post Geriatric Rehabilitation Relates to Successful Outcomes

  • PhotoDr. S. Webber

Award icon $13,000

Spending time in hospital is often a life-changing event for older adults. Routine mobility is reduced which often leads to further disability and additional health problems. Studies in acute care have demonstrated that older patients tend to walk very little (431-1138 steps/day) compared to individuals in the community. However, walking is important and related to life expectancy after people leave the hospital. Little research has been conducted in geriatric rehabilitation settings where patients generally have longer lengths of stay and more medical problems compared to acute care. In addition, previous studies have used only gross measures of walking (i.e., total steps/day) and have not attempted to characterize daily activity bouts in detail. Our pilot data suggests that older patients tend to engage in very short walking bouts (15 steps at a time) and rarely walk for more than three minutes continuously.

The purpose of this project is to investigate activity patterns in geriatric rehabilitation patients to determine aspects important for community living. We will recruit 30 patients at Riverview Health Centre and we will conduct baseline functional tests in the final week before discharge. Patients will wear an activity monitor for five days in hospital and then five days at home to collect detailed activity information as they go about their normal routines. Participants will receive telephone calls one, two, and three months post-discharge to inquire about their use of community resources and the healthcare system in the previous month. The detailed information about activity patterns gathered in hospital and at home will allow us to determine the aspects of activity that are most important in allowing older adults to maintain their independence at home. This will allow us to ensure that therapy adequately prepares patients for a successful discharge.

  • Dr. Sandra Webber — PhD (Physiology and Community Health Sciences) (University of Manitoba) 2010; MSc (Rehabilitation) (University of Manitoba) 1996; BMR(PT) (Physical Therapy) (University of Manitoba) 1990

    Assistant Professor, Physical Therapy, University of Manitoba

    Research Affiliate, Kinesiology and Recreation Management, University of Manitoba

    Research Affiliate, Centre on Aging, University of Manitoba

    Adjunct Professor, College of Graduate Studies and Research, University of Saskatchewan

Temporal and Spatial Trends of Lymphoma Incidence, Survival, and Mortality in Manitoba

  • PhotoDr. X. Ye

Award icon $14,500

Lymphoma is a group of white blood cell cancers that have large impacts on an individual's quality of life and the health of a population.

The overall goal of this project is to examine the changes of lymphoma disease outcomes (incidence, mortality and survival) over time and the disparities across different geographic regions in the province. The data necessary for the studies will be obtained from the Manitoba Cancer Registry.

The results of the project could improve our understanding of lymphoma epidemiological patterns in the province. The project could also generate innovative research ideas about lymphoma development and prognosis; eventually leading to better prevention and lymphoma patient management.

  • Dr. Xibiao Ye — PhD (Epidemiology) (Fudan University) 2003; MSc (Public Health, Epidemiology) (Shanghai Medical University) 1999; MD (Medicine) (Jiangxi Medical College) 1996

    Assistant Professor, Community Health Sciences, University of Manitoba

    Epidemiologist, Centre for Healthcare Innovation, WRHA

Continue reading the next page: Grant Recipients » 2014